Zimmer Biomet Holdings, Inc. (NYSE:ZBH) SVP Lori Winkler Sells 1,443 Shares

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $107.87 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90. The stock has a fifty day moving average price of $105.55 and a 200-day moving average price of $107.22. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm has a market cap of $21.47 billion, a PE ratio of 24.24, a P/E/G ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the business posted $2.20 earnings per share. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Stifel Nicolaus boosted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Raymond James cut their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Truist Financial reaffirmed a “hold” rating and issued a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Finally, Barclays cut their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $124.15.

Institutional Investors Weigh In On Zimmer Biomet

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZBH. Franklin Resources Inc. grew its position in Zimmer Biomet by 398.7% during the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider’s stock worth $369,469,000 after purchasing an additional 2,796,372 shares during the period. Norges Bank acquired a new stake in Zimmer Biomet during the 4th quarter worth about $216,223,000. Dodge & Cox grew its position in Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider’s stock worth $2,019,480,000 after purchasing an additional 2,044,645 shares during the period. Nuveen Asset Management LLC grew its position in Zimmer Biomet by 191.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider’s stock worth $146,763,000 after purchasing an additional 913,310 shares during the period. Finally, Sound Shore Management Inc. CT acquired a new stake in Zimmer Biomet during the 4th quarter worth about $81,447,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.